Last reviewed · How we verify
Y90 Ibritumomab Tiuxetan RIT
At a glance
| Generic name | Y90 Ibritumomab Tiuxetan RIT |
|---|---|
| Also known as | Zevalin |
| Sponsor | Sunnybrook Health Sciences Centre |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) (PHASE3)
- Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma (PHASE3)
- Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma (PHASE2)
- Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma (PHASE2)
- Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma (PHASE2)
- External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma (PHASE1)
- Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Y90 Ibritumomab Tiuxetan RIT CI brief — competitive landscape report
- Y90 Ibritumomab Tiuxetan RIT updates RSS · CI watch RSS
- Sunnybrook Health Sciences Centre portfolio CI